NICE rejects BioMarin's Batten disease drug

[ad_1] The profitability monitoring center in England rejected BioMarin's Brineura (Cerliponase alfa) therapy during the final surveillance. The decision, which was published by the NICE Highly Technological Technology (HST) Committee, marks the …

Read More »